

1537963

JC20 Rec'd PCT/PTO 07 JUN 2005

PATENT

S/N Unknown

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: CHAN et al. Serial No.: Unknown  
Filed: concurrent herewith Docket No.: 11669.0150USW1  
Title: TRANSGENIC MICE EXPRESSING HUMAN CD20 AND/OR CD16

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 495848210 US

Date of Deposit: June 7, 2005

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By:   
Name: David Ortiz

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Commissioner:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted within three months of the filing date of the above-identified application, which is not an application under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked

10/537963

JC20 Rec'd PCT/PTO 07 JUN 2005

as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,



MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: June 7, 2005

By Katherine M. Kowalchyk  
Katherine M. Kowalchyk  
Reg. No. 36,848

KMK/acp

Date Mailed: June \_\_, 2005

JC20 Rec'd PCT/PTO 27 JUN 2005

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b>  (Use several sheets if necessary)	Docket Number: 11669.0150USW1		Application Number: 10/537963
	Applicant: CHAN et al.		
	Filing Date: concurrent herewith	Group Art Unit:	

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		SERFINI et al. <u>Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease.</u> <i>Human Gene Therapy</i> . January 2004, Vol. 15, pages 63-76.
		KAWANAKA et al. <u>Expression of Fc gamma receptor III (CD16 on monocytes during hemodialysis in patients with chronic renal failure.</u> <i>Nephron</i> . January 2002, Vol. 90, No. 1, pages 64-71.

**23552**  
PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	